Evaluating the Past, Present, and Future of Regenerative Medicine: A Global View.

“Evaluating the Past and Present of Regenerative Medicine (RM)” was the first part of an Industry Symposium dedicated to the subject during the 2015 TERMIS World Congress in Boston. This working session presented a critical review of the current RM landscape in Europe and North America with possible projections for the future. Interestingly, the RM development cycle seems to obey the Gartner hype cycle, now at the enlightenment phase, after past exaggerated expectations and discouragements, as suggested by increasing numbers of clinical trials and recent market approvals of RM solutions in both Europe (Glybera and Holoclar® from Chiesi Pharma and Strimvelis® from GSK) and Japan (Remestemcel-L from Mesoblast®). The successful commercial translation of RM research is governed by five major drivers: (i) fully validated manufacturing capability for autologous or allogeneic products, (ii) reimbursement for targeted clinical indications with high and demonstrable medico-economic benefits versus standard of care...

[1]  Chan Hyuk Kim,et al.  Redirection of genetically engineered CAR-T cells using bifunctional small molecules. , 2015, Journal of the American Chemical Society.

[2]  Hafsa Munir,et al.  Mesenchymal Stem Cell Therapy for Autoimmune Disease: Risks and Rewards. , 2015, Stem cells and development.

[3]  I. Yannas,et al.  Wound tissue can utilize a polymeric template to synthesize a functional extension of skin. , 1982, Science.

[4]  M. Pangalos,et al.  Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework , 2014, Nature Reviews Drug Discovery.

[5]  B. Levine,et al.  T Cells Expressing Chimeric Antigen Receptors Can Cause Anaphylaxis in Humans , 2013, Cancer Immunology Research.

[6]  D. King.  The scientific impact of nations , 2004, Nature.

[7]  W Goettsch,et al.  From adaptive licensing to adaptive pathways: Delivering a flexible life‐span approach to bring new drugs to patients , 2015, Clinical pharmacology and therapeutics.

[8]  I. Yannas,et al.  Design of an artificial skin. I. Basic design principles. , 1980, Journal of biomedical materials research.

[9]  H. Green,et al.  Seria cultivation of strains of human epidemal keratinocytes: the formation keratinizin colonies from single cell is , 1975, Cell.

[10]  David L Porter,et al.  Chimeric antigen receptor therapy for cancer. , 2014, Annual review of medicine.

[11]  Paul Morgan,et al.  Can the flow of medicines be improved? Fundamental pharmacokinetic and pharmacological principles toward improving Phase II survival. , 2012, Drug discovery today.

[12]  H. Guadalajara,et al.  Autologous Expanded Adipose-Derived Stem Cells for the Treatment of Complex Cryptoglandular Perianal Fistulas: A Phase III Randomized Clinical Trial (FATT 1 Fistula Advanced Therapy Trial 1) and Long-term Evaluation , 2012, Diseases of the colon and rectum.

[13]  Arnold I. Caplan,et al.  Stem Cells in Regenerative Medicine: Science, Regulation and Business Strategies , 2015 .

[14]  E Bell,et al.  Production of a tissue-like structure by contraction of collagen lattices by human fibroblasts of different proliferative potential in vitro. , 1979, Proceedings of the National Academy of Sciences of the United States of America.

[15]  E. Dolgin.  Next-generation stem cell therapy poised to enter EU market , 2015, Nature Biotechnology.

[16]  Heidi Ledford,et al.  Translational research: 4 ways to fix the clinical trial , 2011, Nature.

[17]  Ed Field.  Projected Growth of the World‐Wide Stem Cell Market , 2016 .

[18]  D. Margolis,et al.  Economic outcomes among Medicare patients receiving bioengineered cellular technologies for treatment of diabetic foot ulcers , 2015, Journal of medical economics.

[19]  L. Babiss,et al.  Indication Transformation Maps and The Challenge of Live Cell Delivery , 2016 .

[20]  Ken Garber,et al.  Biotech industry faces new bottleneck , 2001, Nature Biotechnology.

[21]  M. Flume,et al.  The payers' perspective on gene therapies , 2015, Nature Biotechnology.

[22]  Malorye Allison.  Genzyme backs Osiris, despite Prochymal flop , 2009, Nature Biotechnology.

[23]  S. Riddell,et al.  Combining a CD20 Chimeric Antigen Receptor and an Inducible Caspase 9 Suicide Switch to Improve the Efficacy and Safety of T Cell Adoptive Immunotherapy for Lymphoma , 2013, PloS one.

[24]  S. Boyce,et al.  Biologic attachment, growth, and differentiation of cultured human epidermal keratinocytes on a graftable collagen and chondroitin-6-sulfate substrate. , 1988, Surgery.

[25]  C. Morrison.  $1-million price tag set for Glybera gene therapy , 2015, Nature Biotechnology.

[26]  H. Green,et al.  Formation of a keratinizing epithelium in culture by a cloned cell line derived from a teratoma , 1975, Cell.

[27]  R. Veugelers,et al.  Young leading innovators and the EU's R&D intensity gap , 2010 .

[28]  Francisco Cervantes,et al.  The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts. , 2013, Blood.

[29]  Cody J. Weinberger,et al.  The Scientific Impact of Nations: Journal Placement and Citation Performance , 2014, PloS one.

[30]  Heidi Ledford.  Therapeutic cancer vaccine survives biotech bust , 2015, Nature.

[31]  Sara Reardon,et al.  Leukaemia success heralds wave of gene-editing therapies , 2015, Nature.

[32]  Wilson W Wong,et al.  Synthetic biology in cell-based cancer immunotherapy. , 2015, Trends in biotechnology.

[33]  M. Posch,et al.  Gatekeepers and Enablers: How Drug Regulators Respond to a Challenging and Changing Environment by Moving Toward a Proactive Attitude , 2013, Clinical pharmacology and therapy.

[34]  B. Naughton,et al.  Hematopoiesis on Nylon Mesh Templates Comparative Long‐Term Bone Marrow Culture and the Influence of Stromal Support Cells a , 1989, Annals of the New York Academy of Sciences.

[35]  D. Powell,et al.  A fully human chimeric antigen receptor with potent activity against cancer cells but reduced risk for off-tumor toxicity , 2015, Oncotarget.